TN2013000471A1 - Cycloalkyl-fused tetrahydroquinolines as crth2 receptor modulators - Google Patents

Cycloalkyl-fused tetrahydroquinolines as crth2 receptor modulators

Info

Publication number
TN2013000471A1
TN2013000471A1 TNP2013000471A TN2013000471A TN2013000471A1 TN 2013000471 A1 TN2013000471 A1 TN 2013000471A1 TN P2013000471 A TNP2013000471 A TN P2013000471A TN 2013000471 A TN2013000471 A TN 2013000471A TN 2013000471 A1 TN2013000471 A1 TN 2013000471A1
Authority
TN
Tunisia
Prior art keywords
cycloalkyl
receptor modulators
crth2 receptor
tetrahydroquinolines
fused
Prior art date
Application number
TNP2013000471A
Other languages
English (en)
Inventor
Xianhai Huang
Jason Brubaker
Scott L Peterson
John W Butcher
Joshua T Close
Michelle Martinez
Rachel Nicola Maccoss
Joon O Jung
Phieng Siliphaivanh
Hongjun Zhang
Robert G Aslanian
Purakkattle Johny Biju
Li Dong
Ying Huang
Kevin D Mccormick
Anandan Palani
Ning Shao
Wei Zhou
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47357455&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TN2013000471(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of TN2013000471A1 publication Critical patent/TN2013000471A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/06—Ring systems of three rings
    • C07D221/16—Ring systems of three rings containing carbocyclic rings other than six-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
TNP2013000471A 2011-06-17 2013-11-13 Cycloalkyl-fused tetrahydroquinolines as crth2 receptor modulators TN2013000471A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161498345P 2011-06-17 2011-06-17
PCT/US2012/042336 WO2012174176A1 (fr) 2011-06-17 2012-06-14 Tétrahydroquinolines à fusion cycloalkyle en tant que modulateurs de l'activité du récepteur crth2

Publications (1)

Publication Number Publication Date
TN2013000471A1 true TN2013000471A1 (en) 2015-03-30

Family

ID=47357455

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2013000471A TN2013000471A1 (en) 2011-06-17 2013-11-13 Cycloalkyl-fused tetrahydroquinolines as crth2 receptor modulators

Country Status (25)

Country Link
US (2) US8592383B2 (fr)
EP (1) EP2720545B1 (fr)
JP (1) JP5629403B2 (fr)
KR (1) KR101599157B1 (fr)
CN (1) CN103763924B (fr)
AR (1) AR086931A1 (fr)
AU (1) AU2012271661B8 (fr)
BR (1) BR112013032557A2 (fr)
CA (1) CA2838731C (fr)
CL (1) CL2013003625A1 (fr)
CO (1) CO6821958A2 (fr)
CR (1) CR20130670A (fr)
DO (1) DOP2013000306A (fr)
EA (1) EA025100B1 (fr)
EC (1) ECSP14013156A (fr)
ES (1) ES2613644T3 (fr)
IL (1) IL229508A0 (fr)
MA (1) MA35188B1 (fr)
MX (1) MX2013014900A (fr)
NI (1) NI201300133A (fr)
PE (1) PE20140788A1 (fr)
TN (1) TN2013000471A1 (fr)
TW (1) TW201302711A (fr)
WO (1) WO2012174176A1 (fr)
ZA (1) ZA201308942B (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5952829B2 (ja) 2010-12-23 2016-07-13 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． Ｃｒｔｈ２受容体調節剤としてのキノキサリン類およびアザ−キノキサリン類
US9290453B2 (en) 2010-12-23 2016-03-22 Merck Sharp & Dohme Corp. Quinolines and aza-quinolines as CRTH2 receptor modulators
EP2922539B1 (fr) 2012-10-01 2020-01-15 Merck Sharp & Dohme Corp. Isoquinolines substituées utiles comme modulateurs du récepteur crth2
CN104761437B (zh) * 2015-03-31 2018-06-19 上海康鹏化学有限公司 一种4-溴-2,6-二氟三氟甲氧基苯的制备方法
CN104829556B (zh) * 2015-05-06 2018-01-23 南京信息工程大学 一种由固体光气和氨基硫脲反应制备2‑羟基‑5‑氨基‑1,3,4‑噻二唑的方法
EP3337803B1 (fr) 2015-07-23 2022-08-17 Merck Sharp & Dohme LLC Marqueurs génétiques associés à la réponse aux antagonistes du récepteur crth2
JP7122499B2 (ja) * 2016-06-03 2022-08-22 幸久 村田 がん転移阻害剤

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU693143B2 (en) 1993-12-06 1998-06-25 Cytel Corporation CS-1 peptidomimetics, compositions and methods of using the same
US5510332A (en) 1994-07-07 1996-04-23 Texas Biotechnology Corporation Process to inhibit binding of the integrin α4 62 1 to VCAM-1 or fibronectin and linear peptides therefor
JPH10506608A (ja) 1994-07-11 1998-06-30 アセナ ニューロサイエンシーズ，インコーポレイテッド 白血球接着のインヒビター
US5811391A (en) 1994-08-25 1998-09-22 Cytel Corporation Cyclic CS-1 peptidomimetics, compositions and methods of using same
GB9524630D0 (en) 1994-12-24 1996-01-31 Zeneca Ltd Chemical compounds
US6306840B1 (en) 1995-01-23 2001-10-23 Biogen, Inc. Cell adhesion inhibitors
AU5259296A (en) 1995-04-07 1996-10-23 Warner-Lambert Company Flavones and coumarins as agents for the treatment of athero sclerosis
WO1996040781A1 (fr) 1995-06-07 1996-12-19 Tanabe Seiyaku Co., Ltd. INHIBITEURS PEPTIDIQUES CYCLIQUES D'ADHERENCE CELLULAIRE INDUITE PAR INTEGRINE β1 ET β¿2?
US6034057A (en) 1995-07-06 2000-03-07 Zeneca Limited Peptide inhibitors of fibronectine
US6248713B1 (en) 1995-07-11 2001-06-19 Biogen, Inc. Cell adhesion inhibitors
US5925527A (en) 1997-02-04 1999-07-20 Trega Biosciences, Inc. Tricyclic Tetrahydroquinoline derivatives and tricyclic tetrahydroquinoline combinatorial libraries
GT199900147A (es) 1998-09-17 1999-09-06 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas.
KR100731566B1 (ko) 1999-10-14 2007-06-22 가켄 세야쿠 가부시키가이샤 테트라히드로퀴놀린 유도체
FR2825092B1 (fr) 2001-05-23 2005-01-14 Servier Lab Nouveau derives trycicliques de dihydro-quinoleines, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR2827206B1 (fr) 2001-07-10 2004-04-02 Nature Bois Emballages Procede et dispositif de formage de planchettes, et emballages comportant de telles planchettes
US7534897B2 (en) * 2002-05-16 2009-05-19 Shionogi & Co., Ltd. Indole arylsulfonaimide compounds exhibiting PGD 2 receptor antagonism
PL376156A1 (en) 2002-10-04 2005-12-27 Millennium Pharmaceuticals, Inc. Pgd2 receptor antagonists for the treatment of inflammatory diseases
US7504508B2 (en) 2002-10-04 2009-03-17 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
WO2004035541A1 (fr) 2002-10-15 2004-04-29 Janssen Pharmaceutica, N.V. Derives (piperidine-4-yl)-aminobenzamido a substitution benzyl servant de modulateurs de recepteurs delta-opioides
ES2263015T3 (es) 2002-10-21 2006-12-01 Warner-Lambert Company Llc Derivados de tetrahidroquinolina como antagonistas de crth2.
CA2528774A1 (fr) 2003-06-20 2005-01-27 Coley Pharmaceutical Gmbh Antagonistes des recepteurs toll (tlr) pour petites molecules
US20050038070A1 (en) 2003-07-09 2005-02-17 Amgen Inc. Asthma and allergic inflammation modulators
AR048528A1 (es) 2004-04-07 2006-05-03 Millennium Pharm Inc Compuestos derivados de quinolina como antagonistas del receptor de pgd2 para el tratamiento de enfermedades inflamatorias y composiciones farmacéuticas que los contienen.
CA2594280C (fr) 2004-12-27 2013-04-23 Anja Fecher Derives de 2,3,4,9-tetrahydro-1h-carbazole utilises en tant qu'antagonistes des recepteurs de crth2
UA90706C2 (ru) * 2005-02-24 2010-05-25 Милленниум Фармасьютикалз, Инк. Антагонисты рецептора pgd2 для лечения воспалительных заболеваний
EP1915372B1 (fr) 2005-08-12 2013-11-20 Merck Canada Inc. Derives d'indole en tant qu'antagonistes du recepteur crth2
CA2737460C (fr) 2008-09-22 2016-12-20 Merck Frosst Canada Ltd. Derives d'indole utilisables en tant qu'antagonistes du recepteur crth2
CA2737483A1 (fr) 2008-09-22 2010-03-25 Merck Frosst Canada Ltd. Derives d'indole comme antagonistes du recepteur crth2
AU2009295231A1 (en) 2008-09-22 2010-03-25 Merck Canada Inc. Azaindole derivatives as CRTH2 receptor antagonists
UA105039C2 (uk) * 2009-02-24 2014-04-10 Мерк Шарп Енд Доме Корп. Похідні індолу як антагоністи рецептора crth2
US8927559B2 (en) 2010-10-11 2015-01-06 Merck Sharp & Dohme Corp. Quinazolinone-type compounds as CRTH2 antagonists
JP5952829B2 (ja) 2010-12-23 2016-07-13 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． Ｃｒｔｈ２受容体調節剤としてのキノキサリン類およびアザ−キノキサリン類
US9290453B2 (en) 2010-12-23 2016-03-22 Merck Sharp & Dohme Corp. Quinolines and aza-quinolines as CRTH2 receptor modulators

Also Published As

Publication number Publication date
PE20140788A1 (es) 2014-07-09
JP2014517041A (ja) 2014-07-17
EA025100B1 (ru) 2016-11-30
EA201490031A1 (ru) 2014-12-30
IL229508A0 (en) 2014-01-30
CN103763924B (zh) 2016-05-18
AU2012271661A8 (en) 2016-11-10
NI201300133A (es) 2014-02-28
DOP2013000306A (es) 2014-06-01
CL2013003625A1 (es) 2014-08-01
AU2012271661A1 (en) 2014-01-16
JP5629403B2 (ja) 2014-11-19
US8592383B2 (en) 2013-11-26
KR101599157B1 (ko) 2016-03-02
CA2838731A1 (fr) 2012-12-20
CO6821958A2 (es) 2013-12-31
ES2613644T3 (es) 2017-05-25
EP2720545B1 (fr) 2016-11-30
MA35188B1 (fr) 2014-06-02
KR20140025576A (ko) 2014-03-04
CA2838731C (fr) 2016-08-16
BR112013032557A2 (pt) 2020-09-24
TW201302711A (zh) 2013-01-16
MX2013014900A (es) 2014-02-17
ZA201308942B (en) 2015-05-27
EP2720545A4 (fr) 2015-01-14
AU2012271661B2 (en) 2016-11-03
US20140128367A1 (en) 2014-05-08
AR086931A1 (es) 2014-01-29
WO2012174176A1 (fr) 2012-12-20
AU2012271661B8 (en) 2016-11-10
CR20130670A (es) 2014-02-04
ECSP14013156A (es) 2014-02-28
US20120329743A1 (en) 2012-12-27
CN103763924A (zh) 2014-04-30
EP2720545A1 (fr) 2014-04-23

Similar Documents

Publication Publication Date Title
MX2013007295A (es) Quinoxalinas y aza-quinoxalinas como moduladores del receptor de crth2.
PH12018500960A1 (en) Processes for preparing isoquinolinones and solid forms of isoquinolinones
TN2013000471A1 (en) Cycloalkyl-fused tetrahydroquinolines as crth2 receptor modulators
AU2012284088A8 (en) Heterocyclic compounds and uses thereof
IN2014MN02598A (fr)
EA033544B1 (ru) Производные пиридона в качестве ингибиторов киназы, реаранжированной во время трансфекции (ret)
PH12016502378A1 (en) Substituted dihydroisoquinolinone compounds
PH12015501363B1 (en) Chloro-pyrazine carboxamide derivatives with epithelial sodium channel blocking activity
MX2014012695A (es) Derivados de isoindolona.
MD20140063A2 (ro) Derivaţi de acid benzotiazol-6-il acetic şi utilizarea acestora pentru tratarea unei infecţii HIV
MX2014006026A (es) Derivados de aminopirimidina como moduladores de proteina cinasa 2 rica en unidades repetitivas de leucina (lrrk2).
NZ703162A (en) Heterocyclic modulators of lipid synthesis
MX351305B (es) Antagonistas del receptor de mineralocorticoides.
PH12017501816A1 (en) Azabensimidazoles and their use as amp a receptor modulators
IN2014DN06869A (fr)
TW201613864A (en) Novel compounds
MX2017013877A (es) Compuestos de benzimidazolona y benzotiazolona y su uso como moduladores del receptor ampa.
MX337849B (es) Composiciones y metodos para inhibicion de la via jak.
IN2014DN07636A (fr)
TN2013000346A1 (en) Asymmetric ureas and medical uses thereof
MD20160111A2 (ro) Derivaţi diheterociclici legaţi de cicloalchil
MX2013009386A (es) Nuevos compuestos de azaespirodecanona.
MX2017013885A (es) Compuestos de indolona y su uso como moduladores del receptor ampa.
TN2013000150A1 (en) Co-crystals and salts of ccr3-inhibitors